CCL2 and prostatitis: Together, both in vivo mouse assay (Figures 1–2) and in vitro cell migration assay (Figures 3–4) conclude that ASC-J9® can reduce the prostatitis via reduction of the CD4+ T cell migration to the prostate that involved the modulation of the CCL2 expression (Figures 4–5).